Nasonex Nasal Spray (mometasone furoate monohydrate) is a prescription corticosteroid spray designed for the management of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and pediatric patients. It offers targeted anti-inflammatory action directly at the site of irritation, reducing congestion, sneezing, and rhinorrhea. Clinically proven and widely recommended by allergists and ENT specialists, it provides sustained relief with once-daily dosing, supporting improved respiratory comfort and quality of life.

Features

• Active ingredient: mometasone furoate monohydrate (50 mcg per spray)
• Delivery system: metered-dose, manual pump spray bottle
• Preservative-free formulation (in its aqueous suspension)
• Designed for nasal use only; not for ocular or oral administration
• Each bottle contains 60 metered sprays after initial priming
• Suitable for patients aged 2 years and older (dose adjustment by age)

Benefits

• Reduces nasal inflammation at the source, minimizing systemic exposure
• Provides 24-hour relief from allergic rhinitis symptoms with a single daily dose
• Improves nasal airflow and reduces dependency on oral decongestants
• Prevents recurrence of nasal polyps after surgical removal
• Non-sedating and non-habit forming, supporting long-term management
• Enhances quality of life by restoring normal sleep and daytime function

Common use

Nasonex is primarily indicated for the treatment of seasonal and perennial allergic rhinitis. It is also approved for the prophylaxis of seasonal allergic rhinitis symptoms when initiated 2–4 weeks prior to the anticipated start of the pollen season. Additionally, it is used in adult patients for the treatment of nasal polyps, both as a monotherapy and as an adjunct following polypectomy.

Dosage and direction

For allergic rhinitis in patients 12 years and older: 2 sprays in each nostril once daily (total 200 mcg/day). For maintenance, the dose may be reduced to 1 spray per nostril once daily. For children 2–11 years: 1 spray in each nostril once daily (total 100 mcg/day). For nasal polyps in adults: 2 sprays in each nostril twice daily (total 400 mcg/day). Shake well before use. Prime the pump before first use or if not used for 14 days or more. Blow nose gently before administration. Tilt head slightly forward and insert tip into nostril, pointing away from the septum. Breathe in gently while spraying.

Precautions

Use under medical supervision in patients with recent nasal septal ulcers, nasal surgery, or trauma. Monitor for signs of localized fungal infection (e.g., Candida albicans). Systemic corticosteroid effects may occur with higher than recommended doses or concomitant systemic steroids. Caution in patients with tuberculosis, untreated fungal, bacterial, or viral infections, or ocular herpes simplex. Not recommended for immediate relief of acute asthma episodes.

Contraindications

Hypersensitivity to mometasone furoate or any excipient. Contraindicated in untreated localized nasal infections. Avoid use in patients with active or quiescent tuberculosis infections of the respiratory tract.

Possible side effects

Common side effects (≥1%): headache, pharyngitis, epistaxis (blood-tinged mucus or frank bleeding), nasal burning or irritation. Uncommon: nasal ulceration or perforation, impaired wound healing, blurred vision, glaucoma or cataracts with long-term use. Rare: anaphylaxis, angioedema, adrenal suppression (with excessive doses). Immediate medical attention should be sought for severe nasal irritation, visual changes, or signs of hypersensitivity.

Drug interaction

No clinically significant pharmacokinetic drug interactions have been reported. However, caution is advised with concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole) due to potential increased systemic exposure. Use with other nasal corticosteroids may increase the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression.

Missed dose

If a dose is missed, administer as soon as remembered unless it is nearly time for the next dose. Do not double the dose. Resume the regular dosing schedule.

Overdose

Acute overdose is unlikely due to low systemic bioavailability. Single doses up to 20 times the recommended dose have been administered without adverse effects. Chronic overdose may lead to symptoms of hypercorticism (e.g., moon face, hypertension). Treatment should be symptomatic and supportive. There is no specific antidote.

Storage

Store at 20–25°C (68–77°F); excursions permitted between 15–30°C (59–86°F). Do not freeze. Keep the bottle upright and protected from light. Discard 120 days after first use or when the dose counter reads “0”, whichever comes first. Keep out of reach of children.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis and individualized treatment recommendations. Do not initiate or discontinue therapy without medical supervision.

Reviews

“Prescribed Nasonex for year-round allergies—noticeable improvement in nasal congestion within 3 days. No drowsiness or rebound congestion.” – Maria K., 42
“As an allergist, I find Nasonex to be a reliable first-line therapy for moderate to severe allergic rhinitis. Its safety profile in pediatric patients is well-documented.” – Dr. A. Reynolds, MD
“Effective for nasal polyps post-surgery. Reduced recurrence frequency significantly.” – James L., 58
“Minimal side effects compared to other steroid sprays. The once-daily dosing improves adherence.” – Sarah T., 31